Ancilia Biosciences

Ancilia Biosciences has developed a novel bacterial therapy targeting viral components of the microbiome to address chronic conditions in immunology and oncology indications. Our solution harnesses the natural function of CRISPR to enable a new generation of LBPs to engineer immunity against bacteriophage viruses.